Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb/III study of guselkumab in ulcerative colitis
CTR20201110Phase 3Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of guselkumab in autoimmune colitis, sponsored by Janssen Pharmaceutical. Started Jan 2021; status: active.
02
Drugs
guselkumab
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20201110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201110.